Related Experiment Videos
Systemic therapy in metastatic renal cell carcinoma
1Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland. seppo.pyrhonen@tyks.fi
Summary
Immunomodulating cytokines like interferon-alpha and interleukin-2 offer modest survival benefits for metastatic renal cell carcinoma (RCC). While objective responses are limited, new approaches may improve future treatment outcomes for kidney cancer.
Area of Science:
- Oncology
- Immunology
Background:
- Significant advances in renal cell carcinoma (RCC) biology over the past two decades.
- Metastatic RCC treatment remains challenging, with current options yielding limited durable responses.
Purpose of the Study:
- To review the current therapeutic landscape for metastatic RCC.
- To highlight the efficacy and limitations of cytokine-based immunotherapy.
- To acknowledge emerging investigational approaches.
Main Methods:
- Review of existing literature on metastatic RCC treatments.
- Analysis of response rates and survival data for immunomodulating cytokines.
- Discussion of novel therapeutic strategies.
Main Results:
- Immunomodulating cytokines (interferon-alpha, interleukin-2) provide the best current results for metastatic RCC.
- Objective tumor responses are observed in only 15-20% of patients.
- Long-term survival (5-10%) with durable tumor regression is the realistic expectation.
Conclusions:
- Current cytokine-based therapies offer modest survival benefits for metastatic RCC.
- A small fraction of patients achieve objective tumor responses.
- Promising new investigational approaches are on the horizon for improved outcomes.